b) an excipient.

In still yet another aspect, the present disclosure provides use of a compound described herein in the manufacture of a medicament for the treatment and/or prevention of a disease or a disorder in a patient in need thereof, wherein an amount of the medicament sufficient to treat and/or prevent the disease or disorder is to be administered to the patient. In some embodiments, the present disclosure provides methods of treating and/or preventing a disease or a disorder in a patient in need thereof, comprising administering to the patient a compound or composition described herein in an amount sufficient to treat and/or prevent the disease or disorder.

In some embodiments, the disease or disorder is associated with angiogenesis. In other embodiments, the disease or disorder is associated with fibrosis. In some embodiments, the disease or disorder is associated with fibrosis and/or angiogenesis.

In some embodiments, the disease or disorder is pulmonary, liver, renal, cardiac, and pancreatic fibrosis, scleroderma, scarring, retinopathy of prematurity, familial exudative vitreoretinopathy, proliferative vitreoretinopathies, macular degeneration, diabetic retinopathy, cancer, osteoporosis, autoimmune diseases, humoral hypercalcemia of malignancy, Paget's disease, periodontal disease, psoriasis, arthritis, restenosis, and infection. In some embodiments, the disease or disorder is pulmonary fibrosis. In other embodiments, the disease or disorder is liver fibrosis. In other embodiments, the disease or disorder is cardiac fibrosis. In other embodiments, the disease or disorder is renal fibrosis. In other embodiments, the disease or disorder is pancreatic fibrosis.

In other embodiments, the disease or disorder is scleroderma. In other embodiments, the disease or disorder is scarring. In some embodiments, the scarring is dermal scarring. In other embodiments, the scarring is retinal scarring. In other embodiments, the scarring is corneal scarring.

In other embodiments, the disease or disorder is retinopathy of prematurity. In other embodiments, the disease or disorder is familial exudative vitreoretinopathy. In other embodiments, the disease or disorder is proliferative vitreoretinopathies. In other embodiments, the disease or disorder is macular degeneration. In other embodiments, the disease or disorder is diabetic retinopathy.

In other embodiments, the disease or disorder is cancer. In some embodiments, the cancer includes solid tumor growth or neoplasia. In some embodiments, the cancer includes tumor metathesis. In some embodiments, the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach,



,



, or



or a pharmaceutically acceptable salt or tautomer of any of the above formulas.

33. The compound according to any one of claims 1-32, wherein the compound is effective for inhibiting three or more RGD integrins selected from the group consisting of α5β1, αvβ1, α8β1, αvβ3, αvβ5, αvβ6, and αvβ8, wherein the effectiveness of the compound corresponds to an IC_{50} value of less than 10 nM for each of the three or more RGD integrins as measured using a solid phase receptor assay (SPRA) for function of the respective integrin.

34. The compound according to any one of claims 1-32, wherein the compound has a sustained plasma half life of at least 2 hours as measured in a rat using an iv bolus comprising 1 mg of compound per kg of rat.

35. A pharmaceutical composition comprising:
    a) the compound according to any one of claims 1-34; and
    b) an excipient.

36. Use of a compound according to any one of claims 1-34 in the manufacture of a medicament for the treatment and/or prevention of a disease or a disorder in a patient in need thereof, wherein an amount of the medicament sufficient to treat and/or prevent the disease or disorder is to be administered to the patient.

37. The use of claim 36, wherein the disease or disorder is associated with angiogenesis.

38. The use of claim 36, wherein the disease or disorder is associated with fibrosis.

39. The use of claim 36, wherein the disease or disorder is associated with fibrosis and/or angiogenesis.

40. The use according to any one of claims 36-39, wherein the disease or disorder is pulmonary, liver, renal, cardiac, and pancreatic fibrosis, scleroderma, scarring, retinopathy of prematurity, familial exudative vitreoretinopathy, proliferative vitreoretinopathies, macular degeneration, diabetic retinopathy, cancer, osteoporosis, autoimmune diseases, humoral hypercalcemia of malignancy, Paget's disease, periodontal disease, psoriasis, arthritis, restenosis, and infection.

41. The use of claim 40, wherein the disease or disorder is pulmonary fibrosis.

42. The use of claim 40, wherein the disease or disorder is liver fibrosis.

43. The use of claim 40, wherein the disease or disorder is cardiac fibrosis.

44. The use of claim 40, wherein the disease or disorder is renal fibrosis.

45. The use of claim 40, wherein the disease or disorder is pancreatic fibrosis.

46. The use of claim 40, wherein the disease or disorder is scleroderma.

47. The use of claim 40, wherein the disease or disorder is scarring.

48. The use of claim 47, wherein the scarring is dermal scarring.

49. The use of claim 47, wherein the scarring is retinal scarring.

50. The use of claim 47, wherein the scarring is corneal scarring.

51. The use of claim 40, wherein the disease or disorder is retinopathy of prematurity.

52. The use of claim 40, wherein the disease or disorder is familial exudative vitreoretinopathy.

53. The use of claim 40, wherein the disease or disorder is proliferative vitreoretinopathies.

54. The use of claim 40, wherein the disease or disorder is macular degeneration.

55. The use of claim 40, wherein the disease or disorder is diabetic retinopathy.

56. The use of claim 40, wherein the disease or disorder is cancer.

57. The use of claim 56, wherein the cancer includes solid tumor growth or neoplasia.

58. The use of claim 56, wherein the cancer includes tumor metathesis.

59. The use of claim 56, wherein the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid.

60. The use of claim 56, wherein the cancer is a carcinoma, sarcoma, lymphoma, leukemia, melanoma, mesothelioma, multiple myeloma, or seminoma.

61. The use of claim 40, wherein the disease or disorder is osteoporosis.

62. The use of claim 40, wherein the disease or disorder is an autoimmune disease.

63. The use of claim 62, wherein the autoimmune disorder is multiple sclerosis.

64. The use of claim 40, wherein the disease or disorder is humoral hypercalcemia of malignancy.

65. The use of claim 40, wherein the disease or disorder is Paget's disease.

66. The use of claim 40, wherein the disease or disorder is periodontal disease.

67. The use of claim 40, wherein the disease or disorder is psoriasis.

68. The use of claim 40, wherein the disease or disorder is arthritis.

69. The use of claim 68, wherein the arthritis is rheumatoid arthritis.

70. The use of claim 40, wherein the disease or disorder is restenosis.

71. The use of claim 40, wherein the disease or disorder is an infection.

72. The use of claim 36-71, wherein the patient is a human, monkey, cow, horse, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof.

73. The use of claim 72, wherein the patient is a monkey, cow, horse, sheep, goat, dog, cat, mouse, rat, or guinea pig.

74. The use of claim 72, wherein the patient is a human.